| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5502604 | Journal of the Neurological Sciences | 2017 | 6 Pages |
Abstract
Current limited data suggest that amantadine may be the only drug that has relatively sufficient evidences in treatment of fatigue symptoms in MS. Further RCT studies recruiting larger samples sizes are required to validate the therapeutic effect of these candidate drugs.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Ting-ting Yang, Li Wang, Xiao-yang Deng, Gang Yu,